127 related articles for article (PubMed ID: 35613653)
1. Assessment of hyaluronic acid-modified imatinib mesylate cubosomes through CD44 targeted drug delivery in NDEA-induced hepatic carcinoma.
Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh P; Tabassum H; Alka ; Singh S; Guleria A; Saraf SA
Int J Pharm; 2022 Jun; 622():121848. PubMed ID: 35613653
[TBL] [Abstract][Full Text] [Related]
2. Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma.
Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh S; Singh P; Guleria A; Saha S; Saraf SA
Mol Pharm; 2021 Mar; 18(3):1102-1120. PubMed ID: 33356314
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamic evaluation of hyaluronic acid-modified imatinib-loaded PEGylated liposomes in CD44-positive Gist882 tumor-bearing mice.
Huang J; Chen J
J Liposome Res; 2024 Mar; 34(1):97-112. PubMed ID: 37401372
[TBL] [Abstract][Full Text] [Related]
4. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
5. Appraisal of folate functionalized bosutinib cubosomes against hepatic cancer cells: In-vitro, In-silico, and in-vivo pharmacokinetic study.
Nisha R; Kumar P; Mishra N; Maurya P; Ahmad S; Singh N; Saraf SA
Int J Pharm; 2024 Apr; 654():123975. PubMed ID: 38452833
[TBL] [Abstract][Full Text] [Related]
6. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic-Acid-Tagged Cubosomes Deliver Cytotoxics Specifically to CD44-Positive Cancer Cells.
Pramanik A; Xu Z; Ingram N; Coletta PL; Millner PA; Tyler AII; Hughes TA
Mol Pharm; 2022 Dec; 19(12):4601-4611. PubMed ID: 35938983
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an
Negi LM; Talegaonkar S; Jaggi M; Verma AK
J Drug Target; 2019 Feb; 27(2):183-192. PubMed ID: 29972336
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
[TBL] [Abstract][Full Text] [Related]
10. A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers.
Parashar P; Tripathi CB; Arya M; Kanoujia J; Singh M; Yadav A; Saraf SA
Drug Deliv Transl Res; 2019 Feb; 9(1):37-52. PubMed ID: 30178279
[TBL] [Abstract][Full Text] [Related]
11. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
13. Metformin-Loaded Hyaluronic Acid-Derived Carbon Dots for Targeted Therapy against Hepatocellular Carcinoma by Glutamine Metabolic Reprogramming.
Ghosh A; Ghosh AK; Zaman A; Das PK
Mol Pharm; 2023 Dec; 20(12):6391-6406. PubMed ID: 37933877
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines.
Lompardía S; Díaz M; Pibuel M; Papademetrio D; Poodts D; Mihalez C; Álvarez É; Hajos S
Sci Rep; 2019 Jul; 9(1):10930. PubMed ID: 31358779
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells.
Chen L; Bourguignon LY
Mol Cancer; 2014 Mar; 13():52. PubMed ID: 24606718
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
Jiang S; Li M; Hu Y; Zhang Z; Lv H
Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
[TBL] [Abstract][Full Text] [Related]
17. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
19. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M
Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Song S; Chen F; Qi H; Li F; Xin T; Xu J; Ye T; Sheng N; Yang X; Pan W
Pharm Res; 2014 Apr; 31(4):1032-45. PubMed ID: 24154802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
